NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, Forecast & News

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) released its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by $0.01. View Eiger Biopharmaceuticals' Earnings History.

Eiger Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Eiger Biopharmaceuticals.

6 Wall Street analysts have issued 1-year price objectives for Eiger Biopharmaceuticals' shares. Their forecasts range from $10.72 to $47.00. On average, they expect Eiger Biopharmaceuticals' stock price to reach $29.14 in the next twelve months. This suggests a possible upside of 127.7% from the stock's current price. View Analyst Price Targets for Eiger Biopharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eiger Biopharmaceuticals.

News articles about EIGR stock have been trending very negative recently, InfoTrie reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eiger Biopharmaceuticals earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Eiger Biopharmaceuticals.

Eiger Biopharmaceuticals saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 475,400 shares, a decline of 8.9% from the December 31st total of 521,800 shares. Based on an average trading volume of 175,700 shares, the short-interest ratio is currently 2.7 days. Approximately 2.2% of the shares of the company are short sold. View Eiger Biopharmaceuticals' Current Options Chain.

Some companies that are related to Eiger Biopharmaceuticals include Orchard Therapeutics (ORTX), Mesoblast (MESO), DBV TECHNOLOGIE/S (DBVT), NanoString Technologies (NSTG), Aerie Pharmaceuticals (AERI), Krystal Biotech (KRYS), BAVARIAN NORDIC/S (BVNRY), Sangamo Therapeutics (SGMO), Proteon Therapeutics (PRTO), Vericel (VCEL), Oyster Point Pharma (OYST), AVITA MED LTD/S (RCEL), Atara Biotherapeutics (ATRA), Adverum Biotechnologies (ADVM) and Twist Bioscience (TWST).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger Biopharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), Concert Pharmaceuticals (CNCE), Exelixis (EXEL), Amarin (AMRN), Celldex Therapeutics (CLDX) and Catalyst Pharmaceuticals (CPRX).

Eiger Biopharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Tocqueville Asset Management L.P. (0.21%), Sanders Morris Harris LLC (0.19%) and California Public Employees Retirement System (0.18%). Company insiders that own Eiger Biopharmaceuticals stock include David A Cory, Eldon C Mayer III, Interwest Partners X Lp, Joanne Quan, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Institutional Ownership Trends for Eiger Biopharmaceuticals.

EIGR stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Sanders Morris Harris LLC and Tocqueville Asset Management L.P.. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include David A Cory, Eldon C Mayer III, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Insider Buying and Selling for Eiger Biopharmaceuticals.

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EIGR stock can currently be purchased for approximately $12.80.

Eiger Biopharmaceuticals has a market capitalization of $313.60 million. The biotechnology company earns $-52,390,000.00 in net income (profit) each year or ($3.82) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe.View Additional Information About Eiger Biopharmaceuticals.

The official website for Eiger Biopharmaceuticals is http://www.eigerbio.com/.

Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]